# Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

> **NCT00482625** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 6 (actual)

## Conditions studied

- Intraductal Papillary Mucinous Neoplasm of the Pancreas
- Recurrent Pancreatic Cancer
- Stage IA Pancreatic Cancer
- Stage IB Pancreatic Cancer
- Stage IIA Pancreatic Cancer
- Stage IIB Pancreatic Cancer
- Stage III Pancreatic Cancer

## Interventions

- **DRUG:** erlotinib hydrochloride
- **PROCEDURE:** conventional surgery
- **OTHER:** immunohistochemistry staining method
- **GENETIC:** protein expression analysis
- **PROCEDURE:** biopsy
- **OTHER:** pharmacological study
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00482625
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-06
- **Primary completion:** 2010-02
- **Final completion:** 2013-09
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** The protocol has been completed prematurely (e.g., due to poor accrual, insufficient drug supply, IND closure).
- **Last updated:** 2014-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00482625

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00482625, "Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT00482625. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*